Table 1.
The Laboratory Data of Both Controls and Patients With Community‐Acquired Pneumonia (CAP) Before and After They Received Treatmenta
| Controls (n = 60), | Pretreatment (n = 61), | Posttreatment (n = 61), | |||
|---|---|---|---|---|---|
| Clinical variables | median (range) | median (range) | median (range) | P value UT/Cb | P value UT/Tc |
| Age | 59.38 ± 1.48e | 59.52 ± 2.62e | P = 0.963 | ||
| Gender | |||||
| Male | 36 (60%) | 37 (60.7%) | P = 0.941 | ||
| Female | 24 (40%) | 24 (39.3%) | |||
| Cigarette smoking | |||||
| Yes | 16 (26.7%) | 19 (31.2%) | P = 0.587 | ||
| No | 44 (73.3%) | 42 (68.8%) | |||
| LCN2 (ng/ml) | 17.85 | 50.68 | 31.46 | P < 0.001 | P = 0.057 |
| (5.00–107.50) | (2.07–305.62) | (3.26–305.62) | |||
| LCN2/MMP‐9 complex (ng/ml) | 15.25 | 58.11 | 18.95 | P < 0.001 | P < 0.001 |
| (2.81–75.79) | (6.59–244.08) | (3.41–264.56) | |||
| CRP (mg/dl) | 0.30 | 8.63 | 0.94 | P < 0.001 | P < 0.001 |
| (0.02–1.65) | (0.69–27.40) | (0.30–11.30) | |||
| WBC (/mm3) | 5,860 | 10,890 | 8,450 | P < 0.001 | P < 0.001 |
| (3,110–10,190) | (3,560–32,480) | (3,460–22,340) | |||
| Neutrophils (/mm3) | 3,530 | 8,673 | 5,484 | P < 0.001 | P < 0.001 |
| (1,738–6,046) | (1,032–29,686) | (1,518–21,155) | |||
| PSI score | 79.03 ± 5.92e | ||||
| CURB‐65 scored | 0.88 ± 0.11e | ||||
| APACHE II score | 9.22 ± 0.72e | ||||
CRP, C‐reactive protein; WBC, white blood cell; C, controls; UT, patients with CAP before they received treatment; T, patients with CAP after they received treatment; PSI, Pneumonia Severity Index; APACHE II, Acute Physiology and Chronic Health Evaluation II.
p value < 0.05 was considered significant.
The difference was analyzed using the Mann–Whitney U test.
The difference was analyzed using the Wilcoxon signed ranks test.
A 6‐point score, one point each for confusion, blood urea nitrogen >19 mg/dl, respiratory rate >30/min, low systolic (<90 mmHg) or diastolic (<60 mmHg) blood pressure, and aged >65 years.
Mean ± SE.